Two Indian pharma companies seek to end trials of Merck's molnupiravir in moderate COVID-19
8 October 2021 -

Indian pharmaceutical companies Aurobindo Pharma Ltd (NSE:AUROPHARMA) and MSN Laboratories want to discontinue their respective late-stage trials of US pharmaceutical company Merck & Co's (NYSE:MRK) experimental antiviral drug, molnupiravir, in moderate COVID-19 patients, Reuters news agency reported on Friday.

The expert committee of the Drug Controller General of India (DCGI) stated that both the pharmaceutical companies will continue their separate trials in mild COVID-19 patients.

A joint trial for molnupiravir is also being conducted by five Indian generic drugmakers only in mild COVID-19 patients in an outpatient setting.

In July 2021, pharmaceutical company Hetero announced interim data from a late-stage trial in mild COVID-19 patients and submitted an application for emergency use approval in this patient group, Reuters added.



Related Headlines